Answers are grounded in this paper and cite their sources.
OBJECTIVE: Iodine-123 metaiodobenzylguanidine (I-123 MIBG) scintigraphy is gradually replacing I-131 MIBG scans in the diagnostic workup of neuroblastoma. High-dose I-131 MIBG, however, is commonly used for subsequent therapy in patients with proven MIBG-avid lesions. The objective of this study was to compare the sensitivities of pretherapy I-123 MIBG and post-therapy I-131 MIBG scans for detecting metastatic lesions of neuroblastoma and determine the suitability of post-therapy scans for detecting new metastases. MATERIALS AND METHODS: Pretherapy I-123 MIBG scans and post-therapy I-131 MIBG scans of 126 patients with neuroblastoma were analyzed retrospectively and the number of detected lesions was compared. RESULTS: In 70 patients (55.6% cases), the pretherapy and post-therapy scans were concordant, showing similar MIBG-avid foci. In the remaining 56 patients (44.4% cases), the post-therapy I-131 MIBG scans revealed additional lesions (i.e. a total of 716 lesions) compared with pretherapy I-123 MIBG scans (only 532 lesions). All lesions detected on pretherapy I-123 MIBG scans were revisualized on the post-therapy I-131 MIBG scans, the latter also revealing 184 new MIBG-avid lesions. CONCLUSION: Post-therapy I-131 MIBG scans demonstrate new lesions in almost half of the patients when compared with pretherapy I-123 MIBG scans and therefore are essential to delineate the disease extent.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: